Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

$Nanoviricides (NNVC.US)$ NEWS A Novel Broad-Spectrum Antivi...

NEWS
A Novel Broad-Spectrum Antiviral with Activity Against RSV
NanoViricides announced that its antiviral drug candidate, NV-387, showed complete survival in mice lethally infected with RSV (Respiratory Syncytial Virus) in a recent study.
The study compared NV-387 with the currently approved RSV treatment, ribavirin. While NV-387 led to the complete survival of animals over a 21-day period, ribavirin resulted in the death of all subjects by day 14.
RSV is a major cause of hospitalizations and deaths among children under 5 and adults over 65. The company's NV-387 is aimed to provide a safer and more effective treatment option for these vulnerable groups.
The company has completed Phase 1a/1b human clinical trials for NV-387 with no reported adverse events and plans to advance to Phase II trials for RSV treatment.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
+0
1
Translate
Report
1793 Views
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
719Followers
75Following
4579Visitors
Follow